F. Damian

Characteristics of patients diagnosed with cervical cancer in Brazil: preliminary results of the prospective cohort EVITA study (EVA001/LACOG 0215)

F. Zaffaroni, G. Werutsky, R. D. S. Freitas, 2021, International Journal of Gynecological Cancer.

O001/#331 Empower-cervical 1/GOG-3016/ENGOT-CX9: results of phase 3 trial of cemiplimab vs investigator’s choice chemotherapy in recurrent/metastatic cervical carcinoma

Shin-ichiro Takahashi, A. Oaknin, D. Lorusso, 2021, Oral Abstracts.

EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.

I. Vergote, I. Lowy, C. Ivanescu, 2022, European journal of cancer.

Survival with Cemiplimab in Recurrent Cervical Cancer.

B. Monk, Chih-Long Chang, S. Lheureux, 2022, The New England journal of medicine.

519MO Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis

B. Monk, Shin-ichiro Takahashi, V. Samouëlian, 2022, Annals of Oncology.

Impact of hydronephrosis and kidney function on survival in newly diagnosed advanced cervical cancer

M. F. Jiménez, F. Damian, F. Fernandes, 2022, Gynecologic oncology reports.

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.

Y. Wang, A. Schneeweiss, Ming Yan, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma

B. Monk, Shin-ichiro Takahashi, V. Samouëlian, 2021, Annals of Oncology.

Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate

L. Fein, M. Mano, N. Lazaretti, 2023, Clinical Drug Investigation.